Karuna Therapeutics Submits NDA

9 Likes

''KarXT, a dual M1/M4 muscarinic agonist, represents the first new mechanism of action to treat schizophrenia in several decades, if approved

Submission is supported by data from three positive registrational trials demonstrating consistent and robust reductions of schizophrenia symptoms’’

4 Likes

The phase iii doesn’t release the side effects report ,that’s what I am most concerned about

1 Like

I think the side effects that KarXT has have to do with headache, nausea, high blood pressure. Does not gain weight, etc. They are tiny compared to the current ones, but we will have to see in the future if this is the case.

That’s phase Ii data, I would like to see phase 3 data

1 Like

The only thing I know is that the phase 3 study is called EMERGENT, it should be on the internet